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kinsonian drugs (EUR 1,450; 95% CI: EUR 1,220–1,760) were 
the primary component of costs paid by the health insurance 
(39.6%) and one of the most expensive components of the 
direct costs (24.0%). The highest copayments made by pa-
tients were for antiparkinsonian drugs and medical equip-
ment (58%). Independent determinants of the increased 
costs of antiparkinsonian pharmacotherapy were younger 
age and occurrence of motor fluctuations.  Conclusions: An-
tiparkinsonian pharmacotherapy is one of the major cost 
components of PD-related costs for health insurance. It im-
poses a considerable economic burden on patients and their 
families as well.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 As the global population continues to age, the preva-
lence of neurodegenerative disorders has continuously 
increased. According to the World Population Prospects 
of the United Nations, the number of people aged 60 years 
will increase nearly 3-fold by the year 2050, reaching 2.1 
billion  [1] . The World Health Organization estimated 
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 Abstract 
 Objective: Antiparkinsonian pharmacotherapy is costly and 
the determinants of drug costs in Parkinson’s disease (PD) 
have been poorly investigated. The objective of this study 
was to investigate the costs of PD and antiparkinsonian 
drugs in an Italian cohort of patients and identify cost-driv-
ing factors of drug therapy.  Methods: Seventy outpatients 
with idiopathic PD were recruited in the Department of Neu-
rology, Napoli University, Italy. Data on resource utilization 
were collected for 6 months using a bottom-up approach. 
Clinical status was evaluated using the Unified Parkinson’s 
Disease Rating Scale. Direct and indirect costs were calcu-
lated from the societal perspective (figures of year 2009). In-
dependent determinants of total costs and costs of antipar-
kinsonian drugs were identified using multivariate regres-
sion analysis.  Results: The total costs of PD were EUR 8,640 
(95% CI: EUR 6,700–11,240) per patient over a 6-month peri-
od. Direct costs accounted for 70% of the total costs. Antipar-
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that there are currently 4 million people with Parkinson’s 
disease (PD) worldwide. PD is a common neurodegen-
erative disorder. The incidence rates of PD in Europe are 
8–18 per 100,000 and its prevalence rates are 66–255 per 
100,000  [2–4] . As such, the number of individuals with 
PD in Italy is estimated to be approximately 112,000  [2] .
 Dopamine replacement therapy with levodopa com-
bined with agents that improve its bioavailability and the 
use of synthetic dopamine agonists are the current phar-
macological options for treatment of this disease. Phar-
macotherapy for PD is purely symptomatic as disease-
modifying drugs are not available yet. The disease has a 
chronic progressive course, with motor complications oc-
curring in 70–80% of patients receiving levodopa therapy. 
 Both the increasing prevalence of PD and its progres-
sive disabling course have led to it imposing a consider-
able economic burden on society, individual patients and 
their families. A number of studies investigating the eco-
nomic consequences of PD in different European coun-
tries have been published in the last decade  [5–10] ; how-
ever, data about Southern Europe are still lacking. Fur-
thermore, data on factors that predict an increased 
economic burden related to pharmacotherapy are scarce. 
Antiparkinsonian pharmacotherapy is costly. Drug ther-
apy in most countries is not fully covered by the health 
insurance and thus copayments by patients for antipar-
kinsonian drugs are high  [10–12] . Only one previous 
study investigated the determinants of drug costs using 
multivariate analysis  [10] .
 The objective of this study was to investigate the costs 
of PD and antiparkinsonian drugs in Italy and to deter-
mine independent factors that influence the costs of an-
tiparkinsonian pharmacotherapy. 
 Methods and Patients 
 The study was initiated by the EuroPa (European Cooperative 
Network for Research, Diagnosis and Therapy in Parkinson’s Dis-
ease) study group (www.EuroParkinson.net) in the context of a 
larger international health economics project that is investigating 
the cost of illness in patients with PD  [13] . The participants in the 
study were recruited from the registry of the EuroPa study group, 
a database of approximately 2,000 patients that has been orga-
nized as a research pool for PD. The participants in the EuroPa 
registry are outpatients with idiopathic PD randomized from the 
clinical databases of the outpatient departments of large medical 
centers such as university hospitals. The following countries are 
participating in this international health economics project: Aus-
tria, the Czech Republic, Germany, Italy, Portugal and Russia. 
Cost data from participating countries will be published sepa-
rately in order to provide detailed cost analyses  [11, 12, 14] . The 
Italian cohort study concentrated on additional factors that deter-
mine the costs of antiparkinsonian drugs. The participants in the 
Italian cohort study were recruited from the Italian pool of the 
EuroPa registry and consisted of outpatients (n = 70) with idio-
pathic PD who visited the neurological department of the Napoli 
Federico II University between July 1, 2003, and June 30, 2004. 
The diagnosis was based on the UK Parkinson’s Disease Society 
Brain Bank clinical diagnostic criteria for PD  [15] . The study was 
approved by the local ethics committee and all participants gave 
informed consent.
 Clinical Evaluation 
 Clinical evaluation was performed at baseline. It included a 
complete medical and neurological examination and involved 
documentation of the following clinical data: disease onset and 
time of diagnosis; clinical status as measured by the Unified Par-
kinson’s Disease Rating Scale (UPDRS) parts II and III  [16] ; mo-
tor complications (motor fluctuations, dyskinesias and dystonia); 
non-motor signs (mental and sleep disorders, autonomic dys-
function), and use of antiparkinsonian medication. 
 Cost Evaluation 
 Cost evaluation was performed during 2 visits (at baseline and 
3 months later). During each visit, cost data were collected using 
a comprehensive questionnaire about the consumption of health 
care resources during the preceding 3 months. As such, disease-
related costs over a 6-month period were collected. The health 
economics questionnaire used in this study has been applied in 
previously published studies on neurological diseases  [17–21] . If 
patients had dementia, severe depression or psychosis, the data 
were obtained from the caregivers. Only PD-related costs were 
considered in the analysis. Drug costs included only costs of an-
tiparkinsonian medication in order to reduce the influence of 
non-PD-related costs. Data collection was performed between 
July 1, 2003, and June 30, 2004. The costs were calculated in Euros 
(EUR), using 2004 prices, and then inflated to 2009 Euros using 
the consumer price index. The total costs (direct and indirect 
costs) were calculated from the societal perspective. 
 Direct costs consisted of the costs of statutory health insur-
ance and out-of-pocket costs. The costs for health insurance in-
cluded the following components:
 (1) Inpatient care: sources of cost information were the official 
tariffs of reimbursement for hospitalizations according to the 
Italian diagnosis-related groups 
 (2) Outpatient care and ancillary therapy (physiotherapy, occupa-
tional therapy): sources of cost information were the official 
Italian state tariffs called ‘Nomenclatore Tariffario’. The fees 
were multiplied by the number of outpatient visits or diagnos-
tic procedures within the 6-month period  [22] 
 (3) Drug costs: source of cost data was the official Italian price list 
of drugs  [23] 
 (4) Expenditures on special home equipment: sources of cost data 
were Italian price lists for special equipment  [24] 
 (5) Formal care (care is provided by healthcare professionals, e.g. 
nurses and medical social workers): sources of cost informa-
tion were the price lists of home care agencies  [25] 
 Out-of-pocket costs included the following components:
 (1) Informal care (home care provided by family members and 
friends): the calculation of costs for informal care was per-
formed using the disposable income of primary caregivers, 
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with disposable income defined as the net income after man-
datory deductions such as income tax and social contributions 
 (2) Copayments of patients for treatments, drugs and equipment: 
the amount of copayments was reported by each patient and 
documented in the questionnaires 
 Indirect costs (productivity losses) were calculated using the 
human capital approach  [26] . The loss of productivity due to pre-
mature retirement was calculated as follows: the calendar days 
remaining in the study period prior to the official age of retire-
ment (60 years for women, 65 years for men) were divided by the 
mean number of calendar days per month (30.44), and then mul-
tiplied by the mean gross wage per month in 2004 (EUR 2,320) 
 [27] . The loss of productivity among PD patients and their care-
givers due to sick leave or reduction in working hours was also 
calculated using the mean gross wage.
 Statistical Analysis 
 The software used in the analysis was Stata (release 10.0; Stata-
Corp, College Station, Tex., USA). The means and 95% CI of the 
cost data are presented. The standard nonparametric or normal-
izing methods were not appropriate for a statistical analysis of cost 
variables because the distribution of these data is usually highly 
skewed  [28] . The statistics were performed using the bootstrap-
ping technique, an appropriate and flexible approach to present-
ing and comparing skewed cost data  [28, 29] . Bivariate compari-
sons were performed using the bootstrap t test  [28, 29] . Multi-
variate comparisons were performed using linear regression 
analyses with standard errors estimated using the bootstrapping 
technique. The level of significance was set at  p  ! 0.05.
 Results 
 Demographics and Clinical Features 
 Among the 70 participants in the study, 41 (58.6%) 
were male and 29 (41.4%) female. The mean age of the 
patients was 65.0  8 8.5 years (range: 41–79 years) and the 
average duration of disease at the time of enrollment was 
7.8  8 5.5 years (range: 0.1–30.5 years). At onset of symp-
toms, the patients had a mean age of 57.3  8 8.6 years 
(range: 35–72 years). The demographic and clinical pa-
rameters stratified by age group are shown in  table 1 .
 Costs from Societal Perspective 
 The total semiannual costs from the societal perspec-
tive amounted to EUR 8,640 (95% CI: EUR 6,700–11,240). 
The direct costs were EUR 6,030 (95% CI: EUR 4,700–
7,970) and accounted for 70% of the total costs. The indi-
rect costs (productivity losses) were lower and amounted 
to EUR 2,610 (95% CI: EUR 1,630–4,130). 
 Among the direct costs, the costs of health insurance 
were EUR 3,660 (95% CI: EUR 2,600–5,730) and the out-
of-pocket costs were EUR 2,370 (95% CI: EUR 1,490–
3,120). The costs of health insurance calculated per 6 
months consisted of the following components: inpatient 
care (EUR 830; 95% CI: EUR 360–1,810), outpatient care 
(EUR 90; 95% CI: EUR 80–110), ancillary therapy (EUR 
Table 1.  Demographics and clinical parameters of patients stratified by age groups
<60 years 60–69 years ≥70 years
Total number 18 (25.7) 28 (40.0) 24 (34.3)
Sex
Male 9 (50.0) 19 (67.9) 13 (54.2)
Female 9 (50.0) 9 (32.1) 11 (45.8)
Motor complications
No 10 (55.5) 8 (28.6) 13 (54.2)
Yes 8 (44.4) 20 (71.4) 11 (45.8)
Nonmotor complications
No 5 (27.8) 5 (17.9) 3 (12.5)
Yes 13 (72.2) 23 (82.1) 21 (87.5)
UPDRS II1 10/7 (6–13) 11/10 (8–14) 14/13 (11–17)
UPDRS III1 15/10 (10–20) 15/11 (11–19) 20/22 (15–24)
Duration of disease1, years 5.6/4.4 (3.7–7.5) 8.3/6.9 (5.9–10.6) 8.8/7.7 (6.5–11.1)
Marital status
Married 14 (77.8) 24 (85.7) 17 (70.8)
Divorced 1 (5.6) 2 (7.1) 0 (0.0)
Single 1 (5.6) 1 (3.6) 3 (12.5)
Widowed 2 (11.1) 1 (3.6) 4 (16.7)
V alues denote numbers with percentages in parentheses.
1 Mean/median with 95% CI in parentheses.
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90; 95% CI: EUR 60–130), special equipment (EUR 90; 
95% CI: EUR 40–260), formal care (EUR 1,100; 95% CI: 
EUR 330–3,580) and antiparkinsonian drugs (EUR 1,450; 
95% CI: EUR 1,220–1,760).
 The out-of-pocket costs consisted of costs for informal 
care (EUR 2,030; 95% CI: EUR 1,320–2,860 per 6 months) 
and copayments of patients (EUR 340; 95% CI: EUR 240–
480 per 6 months). The mean net annual income of the 
study participants was EUR 19,820 (95% CI: EUR 18,980–
21,510). The economic burden imposed on the patients by 
PD-related out-of-pocket costs amounted to approxi-
mately 24% of their mean net income (EUR 19,820; 95% 
CI: EUR 18,980–21,510 per year). The main burden of 
home care fell on patient family members and friends. 
The amount of home care per patient per week included 
4 h of professional care and 12 h of informal care. The 
highest copayments were for antiparkinsonian drugs and 
medical equipment. These constituted 58% (EUR 200; 
95% CI: EUR 110–370) of the total copayments.
 Costs of Antiparkinsonian Drugs 
 The costs of antiparkinsonian drugs (EUR 1,450; 95% 
CI: EUR 1,220–1,760) were the primary component of 
the costs paid by the health insurance (39.6%) and one
of the most expensive components of the direct costs 
(24.0%). The costs of nonantiparkinsonian drugs (gas-
trointestinal drugs, cardiovascular drugs, metabolic 
drugs, etc.) were substantially lower (EUR 190; 95% CI: 
EUR 100–310). The study participants were treated with 
the following antiparkinsonian drugs: levodopa (65 pa-
tients; 92.9%), dopamine agonists (54 patients; 77.1%), 
catechol -O- methyl transferase (COMT) inhibitors (12 
patients; 17.1%) and amantadine (6 patients; 8.6%). None 
of the patients received monoamine oxidase B inhibitors 
or anticholinergics. Dopaminergic medication account-
ed for 89.7% of the costs of antiparkinsonian drugs. The 
costs of antiparkinsonian drugs were as follows: EUR 
1,040 (95% CI: EUR 850–1,410) for dopamine agonists, 
EUR 260 (95% CI: EUR 200–340) for levodopa, EUR 240 
(95% CI: EUR 60–180), EUR 10 (95% CI: EUR 0–10) for 
amantadine. Among the dopamine agonists, the highest 
expenditures were on pramipexole (EUR 790; 95% CI: 
EUR 710–930) and apomorphine (EUR 170; 95% CI: 
EUR 100–320).
 The costs of antiparkinsonian pharmacotherapy in-
creased with disease progression. Their distribution in 
quartiles (Q) of UPDRS is shown in  table 2 . The costs of 
levodopa nearly doubled from UPDRS Q1 to UPDRS Q2 
(EUR 150, 95% CI: EUR 110–230 vs. EUR 280, 95% CI: 
EUR 220–237; p = 0.11), but they did not change between 
UPDRS Q2, Q3 and Q4. The costs of COMT inhibitors 
increased between UPDRS Q1 and Q2 by a factor of 3 
(EUR 25, 95% CI: EUR 10–50 vs. EUR 75, 95% CI: EUR 
60–120; p = 0.02) and remained unchanged in UPDRS 
Q2, Q3 and Q4. The expenditures on apomorphine in-
creased with disease progression ( fig.  1 ), whereas the 
costs of other dopamine agonists were comparable at all 
stages. The amount of prescriptions and costs of noner-
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 Fig. 1. Costs of antiparkinsonian drugs 
stratified by disease severity. Cutoff values 
by UPDRS quartile were 13, 23 and 42.
DA = Dopamine agonists. 
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goline drugs was substantially higher than the prescrip-
tions and costs of ergoline drugs (p  ! 0.01).
 Cost-Driving Factors 
 The results of bivariate analysis are displayed in  ta-
ble 2 . Increasing age was associated with decreases in the 
costs of antiparkinsonian drugs. The presence of motor 
fluctuations or dyskinesias increased drug costs by a fac-
tor of 1.7. The patients with depression had 50% higher 
costs of drugs ( table 3 ), and age was inversely correlated 
with costs (in Euro).
 Independent cost-driving factors were identified by 
multivariate analysis ( table 3 ). Dyskinesia and depression 
were found to be independent factors that increased the 
total costs (in Euro). These variables were able to explain 
36.7% (R 2 ) of the variance in total costs ( table 3 ). Young-
er age and occurrence of motor fluctuations were inde-
pendent determinants of the increased costs of antipar-
kinsonian drugs and were able to explain 37.2% of the 
cost variance.
Table 2.  Costs of antiparkinsonian drugs stratified by potential cost-driving factors
n Mean costs
EUR1
95% CI2 Costs (min)
EUR1
Costs (max)
EUR1
p
Age group 0.04
<60 years 18 1,680 1,300–2,190 70 5,110
60–69 years 28 1,510 1,140–1,900 50 3,230
≥70 years 24 1,060 740–1,430 40 2,660
Sex 0.50
Female 29 1,360 990–1,790 40 4,320
Male (m = 0) 41 1,470 1,190–1,820 60 5,110
UPDRS3 0.18
UPDRS Q1 15 1,020 910–1,250 50 2,600
UPDRS Q2 19 1,370 1,220–1,510 100 3,310
UPDRS Q3 17 1,470 1,380–1,620 100 4,320
UPDRS Q4 19 1,570 1,400–1,790 40 5,110
Motor fluctuations 0.02
No 38 1,050 820–1,290 40 2,420
Yes 32 1,870 1,510–2,280 120 5,110
Dyskinesias 0.04
No 49 1,160 910–1,400 40 2,870
Yes 21 2,050 1,620–2,610 150 5,110
Dystonia 0.19
No 53 1,370 1,100–1,640 40 4,320
Yes 17 1,590 1,210–2,270 170 5,110
Freezing 0.11
No 43 1,210 960–1,510 40 4,320
Yes 27 1,760 1,390–2,240 60 5,110
Psychosis 0.18
No 63 1,220 570–2,000 40 5,110
Yes 7 1,450 1,220–1,740 150 2,870
Dementia 0.19
No 65 710 200–1,570 40 5,110
Yes 5 1,480 1,240–1,740 150 1,760
Depression 0.03
No 31 1,130 840–1,450 50 2,660
Yes 39 1,650 1,340–2,060 40 5,110
1  In EUR, 2009 values.
2 95% CI = 95% bootstrap confidence interval using the bias-corrected and accelerated method.
3 UPDRS parts II and III. Cutoff values by UPDRS quartile were 13, 23 and 42.
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 Discussion 
 This study evaluated the costs of PD and antiparkin-
sonian drugs in a cohort of patients in Italy. To the best 
of our knowledge, other cost-of-illness studies of PD in 
Italy are not currently available. As calculated in our 
study, the costs of PD from the societal perspective 
amounted to EUR 17,280 per patient when extrapolated 
to a 12-month period, with annual direct costs of EUR 
12,060. We used a bottom-up approach (i.e. data collec-
tion was performed directly via individuals). The Euro-
pean Brain Council estimated costs of PD in Italy by 
means of a top-down approach, i.e. splitting highly ag-
gregated statistical data such as national statistics, and 
calculated similar direct costs to be EUR 10,105 per pa-
tient per year  [30] . Among the other countries in South-
ern Europe, the costs of PD were only estimated in Spain 
 [31] . Cubo et al.  [31] reported direct costs of EUR 10,524 
per PD patient per year, which was similar to our find-
ings. The annual direct costs of PD in our study were 
comparable to those reported from other Western Euro-
pean countries (EUR 7,920 in Sweden  [5] , EUR 8,160 in 
Germany  [10] , EUR 9,500 in the UK  [32] ) but higher than 
those from countries in Eastern Europe (EUR 6,700 in 
the Czech Republic  [11] , EUR 3,520 in Russia  [12] ) or Asia 
(EUR 630 in India  [33] , EUR 820 in China  [34] ).
 Antiparkinsonian pharmacotherapy was one of the 
most costly components of direct costs in our study (EUR 
2,900 per patient per year). Similar drug costs were re-
ported in cost-of-illness studies from other Southern and 
Western European countries (EUR 2,680 in Spain  [31] , 
EUR 1,420 in Sweden  [5] , EUR 1,680 in the UK  [32] and 
EUR 3,040 in Germany  [10] ). The costs of antiparkinso-
nian drugs in Eastern Europe and Asia were lower (EUR 
1,220 in the Czech Republic  [11] , EUR 980 in Russia  [12] , 
EUR 180 in India  [33] ). One explanation is the difference 
in drug prices between Western and Eastern countries. 
Drug prices in Eastern Europe and Asia were on average 
30–35% lower. The difference in costs could also be ex-
plained by the fact that expensive dopamine agonists are 
much less often prescribed in Eastern Europe and Asia. 
The proportion of patients on dopamine agonists was 
55% in Russia  [12] , 52% in the Czech Republic  [11] and 
30% in India  [33] as compared to 72% in Germany  [10] 
and 77% among the patients included in our study. Treat-
ment with dopamine agonists was more expensive as 
compared to the costs of other antiparkinsonian drugs. 
Dopamine agonists are effective in the treatment of de 
novo PD  [35] and should be considered in national health-
care programs to improve adequate prescription of these 
drugs.
 Disease progression is associated with increasing costs 
of antiparkinsonian drugs  [36] . One of the factors under-
lying this trend is that more frequent prescription of do-
paminergic drugs occurs in patients with higher UPDRS 
scores, while another factor is that apomorphine treat-
ment is used in advanced stages of the disease. In an ear-
lier German study, the use of apomorphine increased 
drug costs in patients with Hoehn and Yahr stage V dis-
ease by a factor of 2.3  [36] . In our study, apomorphine 
Table 3.  Multivariate analysis of cost-driving factors
Total costs (R2 = 0.367) Costs of antiparkinsonian drugs (R2 = 0.372)
B 95% CI p B 95% CI p
Constant 5,998 –11,296; 23,292 0.50 2,240 731; 3,749 0.004
Gender 2,954 –1,809; 7,718 0.22 –224 –679; 230 0.33
Age –39 –319; 241 0.79 –21 –46; –3 0.04
UPDRS II–III 6 –184; 241 0.75 8 –10; 27 0.37
Fluctuations –414 –5,296; 4,468 0.87 581 43; 1,205 0.04
Dyskinesia 3,651 2,426; 9,728 0.03 438 –270; 1,147 0.23
Dystonia 1,853 –1,918; 3,212 0.47 16 –769; 336 0.44
Freezing 6,131 –624; 11,637 0.23 38 –585; 661 0.91
Depression 2,410 1,954; 6,773 0.04 284 –176; 746 0.23
Dementia –2,834 –12,364; 6,696 0.56 1,009 –493; 2,474 0.18
Psychosis 1,269 –5,018; 7,556 0.69 –224 –1,223; 775 0.66
B = Regression coefficient; 95% CI = 95% bootstrap confidence interval using the bias-corrected and accel-
erated method.
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comprised approximately 35% of the expenditures on do-
pamine agonists in the last quartile of the UPDRS though 
the costs of other dopamine agonists did not differ sub-
stantially between early and advanced disease. Similar to 
previous studies, motor complications in our study were 
associated with higher costs of antiparkinsonian phar-
macotherapy  [10, 36] . 
 Several previous studies have investigated cost-driv-
ing factors for PD  [8, 10–12, 32, 34] . Disease severity was 
identified as an independent factor that increased the to-
tal costs of PD in most studies  [8, 10–12, 32, 34] . In our 
analysis, the total costs increased with advancing disease 
progression; however, disease severity was not among the 
independent predictors of costs. It is possible that there 
are country-specific differences in cost-driving factors. 
Motor complications (fluctuations, dyskinesias, dysto-
nia) were among the independent determinants of total 
costs in previous studies  [8, 11] . However, the types of 
motor complications that were identified as independent 
cost drivers differed between studies from different coun-
tries. Determinants of total costs in France were ‘on-off ’ 
fluctuations, while in the Czech Republic, dystonia was 
found to be among the cost predictors. In our Italian co-
hort of patients with PD, dyskinesias were independent 
determinants of total costs. Interestingly, depression was 
identified as a cost-driving factor in our study though the 
majority of previous studies did not include depression in 
their multivariate analysis  [8, 10, 32, 34] . Future large-
scale studies should clarify if depression is a country-spe-
cific, cost-driving, independent factor in the Italian PD 
patient population. Depression is one of the most preva-
lent non-motor symptoms in PD as it affects approxi-
mately 40% of the patients. It is a pivotal factor in reduced 
health-related quality of life and impaired cognitive func-
tion in PD patients  [37, 38] .
 To the best of our knowledge, only one prior study in-
vestigated cost-driving factors of antiparkinsonian drugs 
by multivariate analysis  [10] . Similar to the results of this 
study, we found an inverse association between age and 
the costs of pharmacotherapy. This could be explained by 
the preferable administration of costly dopamine ago-
nists to younger patients with PD.
 Despite a carefully constructed study design, there are 
several potential limitations. First, because our study de-
sign included only one primary center, there is a limited 
possibility to extrapolate these results to the national lev-
el, and thus this study provides only crude cost estimates. 
In addition, because this is a cohort study, a selection bias 
is also possible. An epidemiological approach to patient 
selection may have provided more precise estimations; 
however, the collection of detailed economic data at the 
individual level is time consuming and, as such, the ma-
jority of cost-of-illness studies on PD have used a bottom-
up approach and were performed as cohort studies  [8, 
10–12, 32, 34] . The participants in our study were pre-
dominately in early or moderate disease stages and, there-
fore, the costs of advanced disease were not reflected ad-
equately, including the costs for patients living in nursery 
homes. We also used self-reported questionnaires in our 
study, and thus patient recall may be incomplete, result-
ing in an underestimation of costs. Finally, residual con-
founding by unmeasured variables in the analysis of cost-
driving factors cannot be excluded.
 Conclusion 
 PD imposes a substantial health economics burden on 
both society and patient families in Italy. Antiparkinso-
nian drugs are one of the major cost factors for health 
insurance companies in the context of PD treatment. In 
addition, it imposes a considerable economic burden on 
patients and their families. Drug treatment is most costly 
in younger patients and patients with motor fluctuations. 
Another important finding is the identification of de-
pression among the drivers of total costs. These data 
should be considered in future disease management pro-
grams as a means of improving health care for PD pa-
tients.
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